OncoZenge: De-risked commercial supply through expanded Molteni partnership - Redeye

Redeye leaves a comment following OncoZenge’s announcement of an amended agreement with Molteni Farmaceutici, transferring full responsibility for the commercial-scale manufacturing of BupiZenge to the Italian partner. We view this as a strategically positive development that reinforces OncoZenge's asset-light model and de-risks the commercialization pathway.

Länk till analysen i sin helhet: https://www.redeye.se/research/1142248/oncozenge-de-risked-commercial-supply-through-expanded-molteni-partnership?utm_source=finwire&utm_medium=RSS